ATE264099T1 - Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen - Google Patents

Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen

Info

Publication number
ATE264099T1
ATE264099T1 AT94918217T AT94918217T ATE264099T1 AT E264099 T1 ATE264099 T1 AT E264099T1 AT 94918217 T AT94918217 T AT 94918217T AT 94918217 T AT94918217 T AT 94918217T AT E264099 T1 ATE264099 T1 AT E264099T1
Authority
AT
Austria
Prior art keywords
treatment
methods
pharmaceutical compositions
compositions useful
neurological diseases
Prior art date
Application number
AT94918217T
Other languages
English (en)
Inventor
David John Kyle
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22114083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE264099(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Application granted granted Critical
Publication of ATE264099T1 publication Critical patent/ATE264099T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medical Informatics (AREA)
AT94918217T 1993-06-09 1994-06-02 Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen ATE264099T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7350593A 1993-06-09 1993-06-09
PCT/US1994/006317 WO1994028913A1 (en) 1993-06-09 1994-06-02 Methods and pharmaceutical compositions useful for treating neurological disorders

Publications (1)

Publication Number Publication Date
ATE264099T1 true ATE264099T1 (de) 2004-04-15

Family

ID=22114083

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94918217T ATE264099T1 (de) 1993-06-09 1994-06-02 Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
AT04075413T ATE446101T1 (de) 1993-06-09 1994-06-02 Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04075413T ATE446101T1 (de) 1993-06-09 1994-06-02 Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung

Country Status (11)

Country Link
EP (3) EP2140863A1 (de)
JP (3) JPH08511533A (de)
AT (2) ATE264099T1 (de)
AU (1) AU693450B2 (de)
CA (2) CA2596241C (de)
DE (2) DE69433713T2 (de)
DK (1) DK0707487T3 (de)
ES (2) ES2335991T3 (de)
MX (1) MX263227B (de)
PT (1) PT707487E (de)
WO (1) WO1994028913A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
US5583019A (en) * 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
EP0823475B1 (de) * 1995-04-17 2009-06-17 National Institute of Advanced Industrial Science and Technology Hoch ungesättigte fettsäurenproduzierende mikroorganismen und verfahren zur herstellung von hoch ungesättigten fettsäuren durch verwendung dieser mikroorganismen
IL122405A (en) * 1995-06-07 2003-04-10 Martek Biosciences Corp Methods for preparation of pharmaceutical composition for treatment of specific diseases using oils enriched in dha
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
AU731785B2 (en) * 1996-03-28 2001-04-05 Gist-Brocades B.V. Preparation of microbial polyunsaturated fatty acid containing oil from pasteurised biomass
AU2738497A (en) * 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
DE69711374T3 (de) * 1996-05-15 2007-05-16 Dsm Ip Assets B.V. Verfahren zum extrahieren von sterol mit einem polaren lösungsmittel zur herstellung eines mikrobiellen öles mit niedrigem sterolgehalt
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
JP3792309B2 (ja) 1996-08-30 2006-07-05 サントリー株式会社 不飽和脂肪酸含有油脂の製造方法
JP4633204B2 (ja) * 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
US6344482B1 (en) 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US5993221A (en) * 1997-05-01 1999-11-30 Beth Israel Deaconess Medical Center, Inc. Dietary formulation comprising arachidonic acid and methods of use
FR2782921B1 (fr) 1998-09-09 2002-09-20 Dior Christian Parfums Extrait lipidique de l'algue skeletonema, procede de preparation et utilisation dans des domaines cosmetique et pharmaceutique, notamment dermatologique
DK1121115T4 (da) * 1998-10-15 2011-01-10 Dsm Ip Assets Bv PUFA-tilskud
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
EP1178103A1 (de) 2000-08-02 2002-02-06 Dsm N.V. Reinigung von rohen PUFA-reichen Ölen
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
MXPA04012913A (es) 2002-06-19 2005-03-31 Dsm Ip Assets Bv Proceso de pasteurizacion para celulas microbianas y aceites microbianos.
SE0202188D0 (sv) 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
EP2295529B2 (de) 2002-07-11 2022-05-18 Basf As Verfahren zur Verminderung von Umweltschadstoffen in einem Öl oder einem Fett und Fischfutterprodukt
CA2499983A1 (en) 2002-09-27 2004-04-08 Martek Biosciences Corporation Docohexaenoic acid for improved glycemic control
US20040106584A1 (en) 2002-09-27 2004-06-03 Linda Arterburn Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006077495A1 (en) * 2005-01-24 2006-07-27 Pronova Biocare As Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases
HUE031206T2 (en) * 2005-05-23 2017-06-28 Massachusetts Inst Technology Formulations and methods of application containing PUFA
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
FR2894772B1 (fr) * 2005-12-20 2008-03-14 Pierre Fabre Medicament Sa Procede d'enrichissement en dha
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
NZ569676A (en) * 2005-12-21 2012-03-30 Brudy Technology S L Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
NL1032840C2 (nl) * 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
CN101631542B (zh) 2006-12-28 2011-12-21 三得利控股株式会社 神经再生剂
DE102007031039A1 (de) * 2007-07-04 2009-01-08 Süd-Chemie AG Verfahren zur schonenden Raffination von Pflanzenölen mit Naturbleicherde
WO2010088700A1 (en) * 2009-02-02 2010-08-05 Martek Biosciences Corporation Methods for improving cognitive function and decreasing heart rate
NZ595599A (en) 2009-03-19 2013-12-20 Dsm Ip Assets Bv Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
GB0907601D0 (en) * 2009-05-01 2009-06-10 Equateq Ltd Novel methods
KR101961958B1 (ko) * 2010-06-01 2019-03-25 디에스엠 아이피 어셋츠 비.브이. 세포로부터의 지질의 추출 및 이로부터의 생성물
CN103314291B (zh) * 2010-12-28 2016-05-11 藤野脑研究株式会社 通过血液样品判定痴呆症用的检验方法
MX2013013512A (es) * 2011-05-19 2014-06-05 Us Dept Veterans Affairs Alimento medico para deterioro cognitivo.
WO2013013208A2 (en) * 2011-07-21 2013-01-24 Dsm Ip Assets B.V. Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
JP5496163B2 (ja) * 2011-10-19 2014-05-21 サントリーホールディングス株式会社 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
FR2991337B1 (fr) * 2012-05-29 2016-09-02 Roquette Freres Procede continu d'enrichissement en esters ethyliques de dha d'une huile produite par des microalgues
CN115109804A (zh) 2013-12-20 2022-09-27 玛拉可再生能源公司 从微生物中回收油的方法
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
CA3082441A1 (en) 2016-11-17 2018-05-24 University Of Debrecen Precursor compounds for providing retinoids of the vitamin a5 pathway and uses thereof
AU2017380721B2 (en) 2016-12-22 2021-04-01 MARA Renewables Corporation Methods for producing biomass rich in DHA, palmitic acid and protein using a eukaryotic microorganism
KR101946362B1 (ko) * 2017-10-27 2019-02-11 파이코일바이오텍코리아(주) 뇌 염증성 질환 예방, 개선 또는 치료용 조성물
US12359230B2 (en) 2020-04-03 2025-07-15 MARA Renewables Corporation Microbial oils with high levels of omega-3 fatty acids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
WO1989000606A1 (en) * 1987-07-20 1989-01-26 Maricultura, Incorporated Microorganism production of omega-3 (n-3) lipids
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH01279827A (ja) * 1988-05-02 1989-11-10 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5130242A (en) * 1988-09-07 1992-07-14 Phycotech, Inc. Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
JP2730081B2 (ja) * 1988-09-24 1998-03-25 日本油脂株式会社 微生物によるアラキドン酸含有油脂の製造方法
DE3920679A1 (de) * 1989-06-23 1991-01-10 Milupa Ag Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
EP0568606B1 (de) * 1991-01-24 2001-04-18 Martek Corporation Mikrobielle öle und ihre verwendungen
PH11992043811B1 (en) * 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
CA2121986A1 (en) * 1993-04-26 1994-10-27 Daizo Takeuchi Processes for culturing marine microalgae and producing docosahexaenoic acid using the same

Also Published As

Publication number Publication date
EP0707487B1 (de) 2004-04-14
MX263227B (en) 2008-12-17
DE69435246D1 (de) 2009-12-03
JP2011121978A (ja) 2011-06-23
AU693450B2 (en) 1998-07-02
JPH08511533A (ja) 1996-12-03
DK0707487T3 (da) 2004-08-02
EP2140863A1 (de) 2010-01-06
CA2596241C (en) 2011-04-19
DE69433713D1 (de) 2004-05-19
EP1419780B1 (de) 2009-10-21
ES2335991T3 (es) 2010-04-07
JP2008133286A (ja) 2008-06-12
EP0707487A1 (de) 1996-04-24
WO1994028913A1 (en) 1994-12-22
EP0707487A4 (de) 1998-09-02
DE69433713T2 (de) 2005-04-07
ES2218525T3 (es) 2004-11-16
CA2596241A1 (en) 1994-12-22
CA2164291A1 (en) 1994-12-22
ATE446101T1 (de) 2009-11-15
CA2164291C (en) 2007-10-30
PT707487E (pt) 2004-08-31
AU6963594A (en) 1995-01-03
EP1419780A1 (de) 2004-05-19

Similar Documents

Publication Publication Date Title
ATE264099T1 (de) Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
ATE210979T1 (de) Verwendung rapamycin zur herstellung eines medikaments für die verbeugung und behandlung von hyperproliferativen gefässerkrankheiten, eventuell in kombination mit mycophenolsäure
ATE441667T1 (de) Antikírper für die behandlung von einer immunerkrankung
WO1996040106A3 (en) Methods for controlling highly unsaturated fatty acid content in various tissues
Reding et al. Focused stroke rehabilitation programs improve outcome
DE69110561D1 (de) Mittel zur Behandlung und Vorbeugung von Bauchentzündungen, die als Wirkstoff Zink-L-Carnosin-Salze oder -Komplexe enthalten.
ATE238799T1 (de) Verfahren und mittel zur arzneistoffverabreichung
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
ATE156704T1 (de) Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
GB9519661D0 (en) Fatty acid treatment
DE69624768D1 (de) Ernährungszusammensetzung
ATE143261T1 (de) Zusammensetzung zur behandlung entzündlicher darmerkrankungen
ES2045120T4 (es) Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria.
ATE142500T1 (de) Doppelsträngige rns zur korrektur von abnormalitäten von zirkulierenden immunkomplexen und der monozytenfunktion
ATE69550T1 (de) Salicylsaeurehaltiges mittel gegen schuppende hauterkrankungen.
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
ATE143809T1 (de) Placentaextrakt und verfahren zu seiner herstellung
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen
IT8919216A0 (it) Dispositivo per la cura chirurgica dell'astigmatismo.
TR199801043T2 (xx) Mide-ba��rsak bozukluklar�n�n �nlenmesi ve tedavisi i�in bizmut i�eren bile�imler.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0707487

Country of ref document: EP

REN Ceased due to non-payment of the annual fee